Anesthesia & Patient Safety

GLP-1 Weight-Loss Injections and Anesthesia Risk: Why You Must Tell Your Doctor

Dr. Seyed Ali HejratiNov 6, 20266 min read
GLP-1 Weight-Loss Injections and Anesthesia Risk: Why You Must Tell Your Doctor | کلینیک زیبایی پریسیما (پری-سیما) زعفرانیه تهران

Weekly GLP-1 injections such as Ozempic, Wegovy and Mounjaro can slow stomach emptying and raise the risk of aspiration during anesthesia. Disclosing their use before surgery is essential.

Recently, a case was brought before the forensic medicine authority in which an anesthesiologist was found guilty. A patient was scheduled for a surgical procedure requiring general anesthesia. Before surgery, the patient was stable, all laboratory tests were normal, and both the internist and the anesthesiologist had confirmed that the patient was medically fit for the operation.

The question that came too late

Before the procedure began, the anesthesiologist asked the patient how many hours they had fasted. The patient replied that they had followed the instructions fully and had fasted for a full 10 hours. Once anesthesia was started, the patient developed aspiration (stomach contents entering the lungs) and a severe drop in blood oxygen. Resuscitation efforts were unsuccessful and the patient died.

That is when the situation became critical, because the patient's condition before surgery had been stable and the operation itself was not considered high-risk. A closer review of the patient's circumstances revealed what had happened.

The weight-loss drug the patient did not consider a medication

The patient was using a weekly injectable weight-loss medication from the GLP-1 receptor agonist group, such as Ozempic, Wegovy or Mounjaro. The patient had not mentioned it to the doctor, believing it was simply a slimming product rather than a medication for a chronic condition. The doctor, for their part, had not recorded its use in the medication history and had not asked about it.

The patient was still in the dose-escalation phase and was experiencing delayed gastric emptying, a side effect that is common in the early stages of these drugs. The medication had not been stopped before surgery. When anesthesia began and the stomach had not fully emptied, its contents moved upward, were aspirated into the lungs, and led to falling oxygen levels, acute respiratory failure and, ultimately, death.

What should have been done before surgery

Since this medication was used for weight loss rather than diabetes, stopping it one to two weeks before surgery should have been recommended. The patient should also have been advised to avoid eating for 24 hours before the procedure, while clear fluids could be permitted up to at least 6 hours before the usual fasting period.

Most importantly, a gastric ultrasound should have been performed to assess stomach contents and emptying. If residual food was present, the surgery should have been postponed, unless it was an emergency. In that case, the anesthesiologist must take the special precautions required for such situations.

An important message for patients and clinicians

These medications are now widely prescribed, and patients sometimes start them on their own. For this reason, anesthesia providers should ask every patient, whether male or female, about the use of these drugs, even if the patient has not mentioned them.

If you use GLP-1 medications, tell your doctor and anesthesia team before any procedure or anesthesia. Decisions about stopping or continuing the medication should only be made on your doctor's instructions, and you should never stop it on your own. As use of these drugs continues to grow, this case is unlikely to be the last.